Trinity Capital Inc. Provides $30 Million in Growth Capital to Elucent Medical
Trinity Capital (NASDAQ: TRIN) has committed $30 million in growth capital to Elucent Medical, a medical technology company specializing in guided surgical technologies. Elucent's flagship product, the EnVisio® System, utilizes In-Body Spatial Intelligence™ to provide physicians with 3D surgical awareness through spatial field generation and SmartClip® markers.
The investment follows Elucent's $44 million Series C funding round earlier in 2024. The new capital will support scaling operations and advancing commercialization efforts. The EnVisio® System transforms standard instruments into smart tools, enabling precise soft-tissue surgical excision through continuous 3D positioning data.
Trinity Capital (NASDAQ: TRIN) ha impegnato 30 milioni di dollari in capitale per la crescita a favore di Elucent Medical, un'azienda di tecnologia medica specializzata in tecnologie chirurgiche guidate. Il prodotto di punta di Elucent, il Sistema EnVisio®, utilizza l'Intelligenza Spaziale In-Body™ per fornire ai medici una consapevolezza chirurgica 3D attraverso la generazione di campo spaziale e i marcatori SmartClip®.
L'investimento segue il round di finanziamento Serie C da 44 milioni di dollari di Elucent avvenuto all'inizio del 2024. Il nuovo capitale sosterrà l'espansione delle operazioni e il progresso degli sforzi di commercializzazione. Il Sistema EnVisio® trasforma strumenti standard in strumenti intelligenti, consentendo l'escissione chirurgica precisa dei tessuti molli tramite dati di posizionamento 3D continui.
Trinity Capital (NASDAQ: TRIN) ha comprometido 30 millones de dólares en capital de crecimiento para Elucent Medical, una empresa de tecnología médica especializada en tecnologías quirúrgicas guiadas. El producto insignia de Elucent, el Sistema EnVisio®, utiliza Inteligencia Espacial In-Body™ para proporcionar a los médicos conciencia quirúrgica 3D mediante la generación de campo espacial y marcadores SmartClip®.
La inversión sigue a la ronda de financiación Serie C de 44 millones de dólares de Elucent a principios de 2024. El nuevo capital apoyará la escalada de operaciones y el avance de los esfuerzos de comercialización. El Sistema EnVisio® transforma instrumentos estándar en herramientas inteligentes, permitiendo la excisión quirúrgica precisa de tejidos blandos a través de datos de posicionamiento 3D continuos.
트리니티 캐피탈 (NASDAQ: TRIN)은 엘루센트 메디컬에 3,000만 달러의 성장 자본을 투자했습니다. 엘루센트는 안내된 수술 기술을 전문으로 하는 의료 기술 회사입니다. 엘루센트의 주력 제품인 EnVisio® 시스템은 인바디 공간 인텔리전스™를 활용하여 의사에게 공간 필드 생성과 SmartClip® 마커를 통해 3D 수술 인식을 제공합니다.
이번 투자는 2024년 초에 진행된 엘루센트의 4,400만 달러 시리즈 C 자금 조달 라운드에 따른 것입니다. 새로운 자본은 운영 확장과 상업화 노력을 지원할 것입니다. EnVisio® 시스템은 표준 기구를 스마트 도구로 변환하여 지속적인 3D 위치 데이터를 통해 정밀한 연조직 수술 절제를 가능하게 합니다.
Trinity Capital (NASDAQ: TRIN) a engagé 30 millions de dollars en capital de croissance pour Elucent Medical, une entreprise de technologie médicale spécialisée dans les technologies chirurgicales guidées. Le produit phare d'Elucent, le Système EnVisio®, utilise l'Intelligence Spatiale In-Body™ pour fournir aux médecins une conscience chirurgicale 3D grâce à la génération de champ spatial et aux marqueurs SmartClip®.
L'investissement fait suite à la levée de fonds série C de 44 millions de dollars d'Elucent plus tôt en 2024. Ce nouveau capital soutiendra l'expansion des opérations et les efforts de commercialisation. Le Système EnVisio® transforme des instruments standard en outils intelligents, permettant une excision chirurgicale précise des tissus mous grâce à des données de positionnement 3D continues.
Trinity Capital (NASDAQ: TRIN) hat 30 Millionen Dollar in Wachstumskapital für Elucent Medical bereitgestellt, ein Medizintechnikunternehmen, das auf geführte chirurgische Technologien spezialisiert ist. Das Flaggschiffprodukt von Elucent, das EnVisio®-System, nutzt In-Body Spatial Intelligence™, um Ärzten 3D-chirurgisches Bewusstsein durch die Generierung von räumlichen Feldern und SmartClip®-Markern zu bieten.
Die Investition folgt auf die 44 Millionen Dollar Series C Finanzierungsrunde von Elucent Anfang 2024. Das neue Kapital wird die Skalierung der Abläufe und die Fortschritte bei den Kommerzialisierungsbemühungen unterstützen. Das EnVisio®-System verwandelt Standardinstrumente in intelligente Werkzeuge, die eine präzise Exzision von Weichgewebe durch kontinuierliche 3D-Positionsdaten ermöglichen.
- Secured $30 million growth capital commitment
- Strategic expansion into medical technology sector
- Investment follows successful $44 million Series C funding round
- None.
Insights
The $30 million growth capital commitment to Elucent Medical marks a strategic move in the rapidly expanding surgical navigation market, currently valued at over
The EnVisio® System's technological advantage lies in its unique spatial field generator and SmartClip® marker system, offering real-time 3D surgical awareness - a critical differentiator in a market where precision and efficiency drive adoption. This technology addresses a significant pain point in soft-tissue surgical procedures, where traditional navigation systems often fall short.
For Trinity Capital (TRIN), this investment aligns perfectly with their life sciences portfolio strategy, potentially generating substantial returns through:
- Recurring revenue from disposable SmartClip® markers
- System placements in major surgical centers
- Potential licensing opportunities in adjacent surgical applications
The combination of venture debt following equity funding suggests strong unit economics and near-term commercialization potential, indicating a well-structured deal that balances risk and reward for TRIN shareholders.
Elucent amplifies the field of surgical guidance, transforming standard instruments into smart tools with In-Body Spatial Intelligence™, giving physicians true 3D surgical awareness for unmatched precision. Based in
"Elucent is disrupting the field of surgical guidance with its cutting-edge technology," said Lauren Cosentino, Managing Director, Life Sciences at Trinity Capital. "We are thrilled to be a part of Elucent's journey as they continue to innovate and improve surgical outcomes."
"Our EnVisio® System gives surgeons confidence before, during, and after their surgical procedures so they know they have delivered unparalleled accuracy and precision for their patients. We are in scale mode and are excited to partner with Trinity Capital," said Jason Pesterfield, CEO at Elucent. Trinity Capital's investment will be key to our continued acceleration of our innovation and commercialization efforts."
Earlier in 2024, Elucent raised
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager, aiming to provide investors with stable and consistent returns through access to the private credit market. We source, vet, and invest in dynamic privately funded growth-oriented companies, giving our investors access to a strong and diversified portfolio. With distinct business verticals, Trinity Capital stands as a trusted partner for innovative companies seeking tailored growth capital solutions. Headquartered in
About Elucent Medical:
Elucent Medical is a leading innovator in the field of guided surgical technologies, dedicated to improving patient outcomes through precision and accuracy. The company's flagship technologies, EnVisio® and SmartClip®, offer groundbreaking solutions for soft-tissue surgical guidance with In-Body Spatial Intelligence™ (iSi). With a commitment to innovation and collaboration, Elucent Medical is driving advancements in surgical oncologic care, making a positive impact on the lives of patients and the medical professionals who treat them.
For more information about Elucent Medical and its innovative solutions, please visit www.elucent.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-30-million-in-growth-capital-to-elucent-medical-302359966.html
SOURCE Trinity Capital Inc.
FAQ
How much growth capital did Trinity Capital (TRIN) commit to Elucent Medical in January 2025?
What is the purpose of Trinity Capital's (TRIN) $30 million investment in Elucent Medical?
How much did Elucent Medical raise in their Series C funding round before TRIN's investment?
What is Elucent Medical's main product that Trinity Capital (TRIN) is investing in?
